Session III Abstracts

Click on abstract for more information

Session	Title	Author
TM1	COMPARISON OF THREE COMMERCIAL ENZYME IMMUNOASSAYS AND SUITABILITY OF A RECOMBINANT LINE ASSAY FOR DIFFERENTIATION OF THE INFECTION STATE IN ROUTINE PARVOVIRUS B19 SEROLOGY	Mildred Kirschner, Klaus-Ingmar Pfrepper, Heiko Pfister, Doris Wassenberg, Christine Reichhuber, and Manfred Motz MIKROGEN GmbH, Floriansbogen 2-4, D-82061 Neuried, Germany, Tel: +49 89 54801-191, Fax: +49 89 54801-100
TM2	DRIED BLOOD SPOT (DBS) AS A VALIDATED COLLECTION AND SAMPLE TYPE FOR THE DETECTION OF PARVOVIRUS B19-SPECIFIC IGG AND IGM IN COMMERCIAL EIAs	Jane Nolan, Gary Keating, Gordon Elliott, and Petros Sarantos Biotrin International, 93 The Rise, Mount Merrion, Dublin, Ireland
TM3	EVALUATION OF DRIED PLASMA SPOTS FOR SEQUENCE ANALYSIS OF BLOOD-BORNE VIRUSES	Lauren E. Doherty, Renee Hallack, Lana Gatserelia and Monica M. Parker Wadsworth Center, New York State Department of Health, Albany, NY
TM4	LONG-TERM STABILITY OF VIRAL MARKERS IN PLASMA	PE Garrett, L Miller, B Anekella, and MM Manak SeraCare Life Sciences, Inc., Milford, MA USA
TM5	IMPROVED SIGNAL-TO-CUTOFF RATIO THRESHOLD FOR HBsAg CONFIRMATORY TESTING OF CLINICAL SERUM SPECIMENS REACTIVE BY THE VITROS HBsAg ASSAY	Theodore J. Stier, John R. Attewell, Dane L. Granger, David W. Majewski, and Joseph D. C. Yao Division of Clinical Microbiology, Mayo Clinic, Rochester, MN, U.S.A.
TM6	PREVALENCE OF HEPATITIS A VIRUS (HAV) AND HEPATITIS B VIRUS (HBV) IN PATIENTS FROM MARACAIBO, VENEZUELA	Callejas D., Cuadra C., Estevez J., Porto-Espinoza L., Monsalve-Castillo F., Costa-Leon L., and Gómez L.P. Laboratorio Regional de Referencia Virológica, Escuela de Bioanalisis, Maracaibo and Venezuela. Instituto de Investigaciones Clinicas, Universidad d
TM7	Abstract Withdrawn
TM8	HBV DNA QUANTITATED BY COBAS TAQMAN REAL-TIME PCR: THE MANUAL HIGH PURE COMPARED TO COBAS AMPLIPREP EXTRACTION TECHNIQUES	R. Chan and W.S. Nichols Division of Molecular Pathology, Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048
TM9	MANUAL QIAGEN VS ROCHE AMPLIPREP -TNAI- EXTRACTION OF HBV DNA FOR ASSAY WITH THE ROCHE HBV TAQMAN ASR	Max Arens1, Laura Blair1, Magda Dwidar1, Sheila Mason1 and Jack Baty2 1Department of Pediatrics and 2Division of Biostatistics, Washington Univ. School of Medicine, St. Louis, MO
TM10	COMPARISON OF MULTICODE®-RTx HCV ASSAY WITH COBAS® TAQMAN HCV ASR	Max Arens1, Katherine Cavaletti1, Magda Dwidar1, Scott C. Johnson2, Elizabeth K. Mulligan2, Andrew C. Newman2 and Slava Elagin21Department of Pediatrics, Washington Univ. School of Medicine, St. Louis, MO and 2EraGen Biosciences, Inc., Madison, WI
TM11	PERFORMANCE EVALUATION OF THE COBAS® AMPLIPREP/ COBAS® TaqMan® HCV TEST	R. Mills and S. Young TriCore Reference Laboratories, Albuquerque, NM
TM12	ARUPs EXPERIENCE WITH THE ROCHE HCV CAP/CTM DIAMOND STUDY	Michael T. Pyne1 and David R. Hillyard1,2ARUP Institute for Clinical and Experimental Pathology®1 and University of Utah Department of Pathology2
TM13	QUANTIFYING HEPATITIS C VIRUS (HCV) RNA: THREE PCR INSTRUMENT PLATFORMS COUPLED WITH MANUAL OR ROBOTIC INSTRUMENT SAMPLE EXTRACTION	Carolyn B. Kalinka, Jean B. Myers, and Daniel Amsterdam Erie County Medical Center and School of Medicine and Biomedical Sciences, Buffalo, NY 14215, U.S.A.
TM14	Abstract Withdrawn
TM15	EVALUATION OF THE COBAS AmpliPrep/COBAS TaqMan SYSTEM FOR HCV QUANTIFICATION	A.E. Rendo, I. Rankin, A.A. Young, B. Shifrin, and S.G. Jenkins Mt. Sinai Medical Center, NY, NY
TM16	EVALUATION OF THE AUTOMATED COBAS® AMPLIPREP/COBAS® TAQMAN® ASSAY FOR QUANTITATION OF HCV	Marjorie J. Miller and Michael A. Lewinski Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA
TM17	THE EFFECT OF SPECIMEN PROCESSING AND STORAGE CONDITIONS ON THE STABILITY OF HEPATITIS C VIRUS RNA IN SERUM AND PLASMA	Safedin H. Beqaj1, Shellee Stephens2, Vickie Clinard2and Samuel A. Smith2 1DCL Medical Laboratories Indianapolis, IN and 2PathGroup Labs Nashville, TN
TM18	COMPARISON OF MULTICODE®-RTX HCV (ERAGEN BIOSCIENCES) AND VERSANT® HCV RNA 3.0 bDNA (SIEMENS) HEPATITIS C VIRAL LOAD ASSAYS	Kimberly A. Vaughan1, Diane S. Podzorski1, and Nathan A. Ledeboer1,2 1Dynacare Laboratories and 2Department of Pathology, Medical College of Wisconsin Milwaukee, WI
TM19	TH-1 (IL-2) AND TH-2 (IL-10) IMMUNE RESPONSES OF AMERINDIANS WITH CHRONIC INFECTION BY HEPATITIS B IN THE JAPREIRA COMMUNITY, ZULIA, VENEZUELA	Moreno, Y.1, Monsalve-Castillo, F.2, Costa-Leon. L.2, Atencio, R.3, and Pons, H.4 1Faculty of Experimental Sciences, University of Zulia, 2Virology Cathedra, Bioanalisis School, University of Zulia, 3Regional Laboratory of Virology Reference, and 4Univer
TM20	CONTROL OF HEPATITIS C VIRUS INFECTION IN PATIENTS UNDERGOING DIALYSIS TREATMENT IN MARACAIBO, VENEZUELA	Monsalve-Castillo, F.1, Gómez Gamboa, L.2, Albillos, A.3, and Álvarez De Mon, M.41Virology Cathedra, Bioanalisis School, University of Zulia, Venezuela, 2Bacteriology Laboratory, Adolfo Pons Hospital, 3Gastroenterology Services, Hospital University Ramón
TM21	LOW PREVALENCE OF HEPATITIS C VIRUS IN A PRISONER POPULATION FROM MARACAIBO, VENEZUELA	Monsalve-Castillo, F.1, Chacín-Bonilla, L.2, Atencio, T.R.3, Porto, R.L.3, Costa-León, L.1, stévez, J.4, and Callejas-Valero, D. 3 1Virology Cathedra, Bioanalisis School., 2Inmunology Post-graduate Investigation Clinic Institute, 3Regional Laboratory o
TM22	SVR IS INDEPENDENT OF BASELINE HCV RNA LOAD IN PATIENTS TREATED WITH HIGH DOSE INTERFERON INDUCTION THERAPY	Huub C Gelderblom1,2, Christine J Weegink2, Hans L Zaaijer1, Peter LM Jansen2, Janke Schinkel1, Henk W Reesink2, and Marcel GHM Beld1 1Section of Clinical Virology, Department of Medical Microbiology, and 2AMC Liver Center, Department of Gastroenterology
TM24	PERFORMANCE OF A MULTICODE®-RTX HCV ASSAY AMONG CLINICAL SPECIMENS CONTAINING HCV GENOTYPES 1 TO 6	Jeffrey J. Germer1, Scott C. Johnson2, Elizabeth K. Mulligan2, Andrew C. Newman2, Slava A. Elagin2, and Joseph D.C. Yao11Mayo Clinic, Rochester, Minnesota, and 2EraGen Biosciences, Madison, Wisconsin
TM25	INCLUSION OF A SECOND SCREENING ASSAY TO DETERMINE THE SEROLOGIC CONFIRMATION OF HCV ANTIBODIES AMONG AN HIV POSITIVE POPULATION FROM ARGENTINA	Mammana Lilia, Fernandez Giuliano S., Gaweda A., Mingrone H.1, Cahn P2 ,Quarleri J.3, Salomon H 3, and Bouzas Maria B. 1Unidad de Virologia, Consultorios Externos. Hospital de Infecciosas, ¨2F.J.Muñiz¨. Infectologia Hospital Fernandez, and 3GCBA. Centr
TM26	ABBOTT REALTIME HIV-1 ASSAY: A VIRAL LOAD ASSAY WITH HIGHLY RELIABLE AND REPRODUCIBLE RESULTS	Klara Abravaya, George Schneider, Eric Shain, John Clemens, Ning Tang, Shihai Huang, John Salituro, and Wai-Bing Mak Abbott Molecular Inc. Des Plaines, IL
TM27	EVALUATION OF THE ABBOTT HIV-1 QUANTITATIVE REAL TIME PCR ASSAY	Michelle Bent-Morgan1, Loree C. Heller1,2, John Madison3and Raymond H. Widen1,2 1Esoteric Testing/R&D Section, Tampa General Hospital, Tampa FL, 2University of South Florida College of Medicine, Tampa, FL and 3Clinical Virology Laboratory, Nationwide C
TM28	EVALUATION OF EFFECTS OF PLASMA SAMPLE HANDLING AND POTENTIAL INTERFERING DISEASE STATES ON VERSANT® HIV-1 RNA 1.0 ASSAY (KPCR) PERFORMANCE	C Lin, S Tam, H Huang, C Wagner, P Swiatkowski, S Nicol, J Surtihadi, and G. Gorrin Siemens Healthcare Diagnostics, Tarrytown, NY, US
TM29	VERIFICATION OF THE HIV REAL-TIME PCR ASSAY COBAS AMPLIPREP/COBAS TAQMAN 48 HIV-1 TEST COMPARISON WITH THE SIEMENS bDNA VERSANT HIV-1 V 3.0 ASSAY	A Anga*, KL McRae, G Caldito, J Vanchiere, and JM Matthews-Greer Louisiana State University Health Sciences Center at Shreveport jgreer@lsuhsc.edu
TM30	MULTICENTER EVALUATION OF THE VERSANT® HIV-1 RNA 3.0 ASSAY [bDNA] WITH THE VERSANT 440 MOLECULAR SYSTEM	Jill C. Hanson1, Carl Bommersbach1, Lois White2, Odette Lualhati2, Lilia del Rosario3, Linda Wong3, Jen Shieh2, P. Shawn Mitchell1, Joseph D. Yao1, Mark Stanley2, Jan Turczyn3, Margaret Jankowski-Hennig4, Mark Martin4, James Dicanzio4, and Gillian Morgan4
TM31	COMPARISON OF THE MEASUREMENT OF HIV RNA VIRAL LOAD USING ROCHE COBAS® AMPLIPREP®\COBAS® TAQMAN® ASSAY VS. ROCHE COBAS AMPLICOR ASSAY	Marlin Benedet1, Xiaoli Pang1,3, Linda Chui1,3, Jane Kaczmer2, Roberta Lundeberg1 and Bonita Lee1,4 1Provincial Public Health Laboratory, Edmonton, 2Provincial Public Health Laboratory, Calgary, 3Departent of Laboratory Medicine & Pathology, and 4Departm
TM32	THE ROCHE AMPLIPREP-TAQ 48 SYSTEM FOR HIV-1 QUANTIFICATION IMPROVES THE PERFORMANCE AND DECREASES TECHNICAL TIME COMPARED TO THE ROCHE COBAS AMPLICOR SYSTEM	Shannon Sackett, Marichu Pereira, and Bruce K. Patterson Stanford University Medical Center
TM33	DILUTION OF SMALL VOLUME SAMPLES FOR PEDIATRIC HIV-1 VIRAL LOAD REAL-TIME PCR TESTING	C. Renee Webb1, Ruth Ann Luna2,3, Conchita Almedina de Palacios1, Trang T. Ton1, and James Versalovic2,3 1Department of Pathology, Texas Children?s Hospital, Houston, TX, 2Departments of Pathology, and 3Molecular Virology & Microbiology, Baylor College of
TM34	EVALUATION OF THE ROCHE CAP/CTM HIV-1 ASSAY	Michael T. Pyne1 and David R. Hillyard1,2 ARUP Institute for Clinical and Experimental Pathology®1 and University of Utah Department of Pathology2
TM35	INCIDENCE OF TRANSIENT DETECTABLE HIV-1 VIREMIA ("BLIPS") WHEN MEASURED BY bDNA METHODOLOGY (VERSANT, 3.0, SIEMENS) IS LOWER THAN HISTORICAL INCIDENCE RATES MEASURED BY PCR (AMPLICOR 1.5, ROCHE DIAGNOSTICS)	Patrick M. Nemechek, D.O. Nemechek Health Renewal, Kansas City, Missouri, United States pnemechek@healthrenewal.org
TM36	GENOTYPIC ANALYSIS RESULTS OF NEWLY POSITIVE, LOW-LEVEL VIRAL LOADS (HIV RNA <250 COPIES/ML) PERFORMED BY bDNA (VERSANT, 3.0, SIEMENS) HAVE A SIMILAR CLINICAL IMPACT ON ANTIRETROVIRAL THERAPY DECISIONS AS DO HIGHER LEVEL NEWLY POSITIVE VIRAL LOADS (HIV RN	P Nemechek Kansas City, Missouri, United States
TM37	A NOVEL SYSTEM TO PRODUCE FULLY INFECTIOUS HIV-1 AND ITS USE IN THE DETERMINATION OF RESISTANCE TO PROTEASE, REVERSE TRANSCRIPTASE, & INTEGRASE INHIBITORS IN A SINGLE ASSAY	M.E. Quiñones-Mateu1, K.R. Henry2, J. Weber1, R. Gibson2, A.C. Vazquez1, Y. Gao2, J. Weberova1, D.M. Dudley2, K.N. Nelson2, I. Nankya 2, and E.J. Arts2 1Diagnostic HYBRIDS, Inc., Cleveland, Ohio and 2Case Western Reserve University, Cleveland, Ohio
TM38	DEVELOPMENT OF A GENOTYPING ASSAY FOR HIV-1 INTEGRASE	Sunil D. Pandit, Hitesh Kapur, and Arejas J. Uzgiris Strategic Marker Development, Siemens Healthcare Diagnostics, 725 Potter Street, Berkeley, CA 94710
TM39	SEQUENCE-SPECIFIC VISUAL DETECTION OF AMPLIFIED HIV-1 BY LAMP/ RT-LAMP	Kelly A. Curtis, Donna L. Rudolph, and S. Michele Owen Centers for Disease Control and Prevention, Atlanta ,GA, USA
TM40	AMPLICOR HIV-1 DNA PCR TEST VERSION 1.5 USING 100 UL OF WHOLE BLOOD AND 200 UL OF SPECIMEN DILUENT	Estelle Piwowar-Manning, LeTanya Johnson-Lewis, Susan H. Eshleman, and J. Brooks Jackson School of Medicine, Department of Pathology, Johns Hopkins University
TM41	ANALYSIS OF RAPID ORAQUICK HIV-1/2 TEST IN SERA WITH POSITIVE HIV-1/2 EIA BUT UNCONFIRMED HIV-1 WESTERN BLOT RESULTS	Y.F. Wang1,2, A. Suantio1, B.Y. Chang1, and S. Merritt2. 1Emory University School of Medicine and 2Grady Memorial Hospital, Atlanta, GA, USA
TM43	ANONYMOUS UNLINKED SEROPREVALENCE OF HUMAN MMUNODEFICIENCY VIRUS (HIV) ANTIBODY IN THREE EMERGENCY DEPARTMENTS-USING POOLED SERA TESTING	J.K. Preiksaitis1, J. Fenton1, L. Mashinter2, S. Houston3, and B. Rowe3 1Provincial Laboratory for Public Health, Edmonton, AB, 2Capital Health, Edmonton, AB, and 3University of Alberta Hospital, Edmonton, AB
TM44	STABILITY OF HIV-1 VIRAL LOAD FROM DRIED PLASMA USING	RM Lloyd Jr1, M Holodniy2, RL Mathis1, WA O?Brien1, JL Cooper1, and PM Feorino1 1Research Think Tank, Inc., Buford, GA and 2VA Palo Alto Healthcare System, Palo Alto CA
TM45	COMPARISON OF SENSITROP II, A SECOND GENERATION MOLECULAR HIV CO-RECEPTOR TROPISM ASSAY, TO TROFILE, A CELL-BASED HIV CO-RECEPTOR TROPISM ASSAY, ON TREATMENT EXPERIENCED HIV PATIENT SPECIMENS	Ed Webb, Laura Li, Ph.D., Aaron Reposar and Terry Robins, Ph.D. Pathway Diagnostics, Malibu, CA 90265
TM46	DISTRIBUTION OF HPV GENOTYPES AND CORRELATION OF THE PRETECT HPV-PROOFER TEST IN INVASIVE CERVICAL CANCER IN INDIA	Partha Basu1, Petter Gronn2, Ivan Silva2, Maqsood Siddiqi3, and Sam Ratnam4 for the study group 1Chittaranjan National Cancer Institute, India, 2Norchip, Klokkarstua, Norway, 3Cancer Foundation of India, and 4Public Health Laboratory, St. John?s, Canada
TM47	A MULTI-CENTER STUDY OF THE REPRODUCIBILITY CHARACTERISTICS OF TWO INVESTIGATIONAL USE ONLY HPV TESTS	Joellen Ledford1, Neil Quigley, Ph.D.1, Denise I. Quigley, Ph.D.2, Debra Kohn3, and Belinda Yen-Lieberman, Ph.D.3 1Molecular Pathology Laboratory Network, Maryville, TN; 2Medical University of South Carolina, Charleston, SC, and 3Cleveland Clinic Foundati
TM48	EVALUATION OF INVADER® HPV REAGENTS (ASR) FOR THE DETECTION OF HUMAN PAPILLOMA VIRUS COMPARED TO THE HYBRID CAPTURE® 2 HIGH-RISK HPV DNA TEST	Rosemary Hankerd, Phyllis Schooler, and Duane Newton Department of Pathology, University of Michigan Hospitals and Health Centers, Ann Arbor, MI
TM49	EVALUATION OF THE ANALYTICAL PERFORMANCE OF A HUMAN PAPILLOMAVIRUS GENOTYPING ASSAY: THE INFINITI HPV-QUAD ASSAY	Maria Erali1, David C. Pattison1, Carl T. Wittwer1, 2 and Cathy A. Petti1, 2 1ARUP Institute for Clinical and Experimental Pathology and the 2Department of Pathology, University of Utah, Salt Lake City, UT
TM50	MALDI-TOF MASS SPECTROMETRY FOR HUMAN PAPILLOMAVIRUS GENOTYPING	Maria Erali1, David C. Pattison1, Jay Stoerker2 and Karl V. Voelkerding 1, 3 1ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, 2SensiGen, Ann Arbor, MI, and 3Department of Pathology, University of Utah, Salt Lake City, UT
TM51	CHARACTERIZATION OF THE ANALYTICAL PERFORMANCE OF THE INVESTIGATIONAL USE ONLY INVADER HPV 16/18 MOLECULAR ASSAY	Michelle Curtis, LuAnne Chehak, Angela Hudson, Andrea Mast, Sarah Olson, Tamara Sander, and Marilyn Olson Third Wave Technologies, Inc., Madison, WI, USA
TM52	ANALYTICAL PERFORMANCE CHARACTERISTICS OF THE INVESTIGATIONAL USE ONLY INVADER HPV HR MOLECULAR ASSAY	Michelle Curtis, LuAnne Chehak, Angela Hudson, Andrea Mast, Sarah Olson, Tamara Sander, and Marilyn Olson Third Wave Technologies, Inc., Madison, WI, USA
TM53	EVALUATION OF INVADER HPV ASR AS AN ALTERNATIVE FOR THINPREP SPECIMENS WHERE QUANTITY IS NOT SUFFICIENT FOR HYBRID CAPTURE 2 TESTING	M.B. Nye, R.N. Amos, E. Christensen, S. Anderson and B.A. Body Laboratory Corporation of America, Burlington, NC
TM54	PERFORMANCE OF A LAB-DEVELOPED ASSAY USING INVADER HPV ASR ON 1000 CONSECUTIVE THINPREP SPECIMENS AND COMPARED WITH HYBRID CAPTURE 2 AND CYTOLOGY RESULTS	M.B. Nye, R.N. Amos, E. Christensen, S. Anderson and B.A. Body Laboratory Corporation of America, Burlington, NC
TM55	COMPARISON OF THE DIGENE HYBRID CAPTURE 2 ASSAY AND THE THIRD WAVE TECHNOLOGIES INVADER HPV ASR	SL Gallagher, JP Dang, BJ. Dokus, AB Hawk, V Padmanabhan, and GJ Tsongalis Department of Pathology, Dartmouth Medical School, Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH
TM56	COMBINED HPV GENOTYPING AND CELL-BASED E6, E7 MRNA (HPV ONCOTECT) DETECTION IN CERVICAL CYTOLOGY SPECIMENS PERFORMED ON A MOLECULAR HYBRID PLATFORM (MOHP) MAXIMIZES SENSITIVITY AND POSITIVE PREDICTIVE VALUE FOR BIOPSY-PROVEN CIN 2 OR ABOVE	Gerald Coquillard and Bruce K. Patterson Stanford University Medical School
TM57	HPV E6, E7 mRNA EXPRESSION IN ECTOCERVICAL CELLS (HPV ONCOTECT) PREDICTS DISEASE PROGRESSION IN WOMEN WITH LOW GRADE INTRAEPITHELIAL NEOPLASIA (LSIL)	Francisco Alameda, Bibiana Pilao, and Bruce K. Patterson Hospital Del Mar (Spain), Labec Pharma (Spain), and Stanford University Medical School
TM58	TGF-B1 IN SERUM AND BIOPSY OF WOMEN WITH PRE INVASIVE LESIONS OF THE UTERINE CERVIX INFECTED OR NOT WITH PAPILLOMAVIRUSES HUMAN	Diana Callejas1, Ricardo Atencio1, Jose Nuñez-T2, Leticia Porto1, Yenddy Carrero1, Raimy Mindiola1, Luciana Costa3, and F. Monsalve3 1Laboratorio Regional de Referencia Virológica, Instituto de Investigaciones Clínicas ?Dr. Américo Negrette?, Universidad
TM59	IL-2, IL-10 AND IL-2R DETERMINATION IN PATIENT BIOPSY AND SERUM WITH UTERINE CERVIX PREINVASIS LESIONS HUMAN PAPILLOMAVIRUS INFECTION	Mindiola Raimy1, Jesus Mosquera2, Diana Callejas1, Ricardo Atencio1, Jose Nuñez-T3, Leticia Porto1, Yenddy Carrero1, and Cuadra Cesar4 1Laboratorio Regional de Referencia Virológica, 2Instituto de Investigaciones Clínicas ?Dr. Américo Negrette?, 3Universi
TM60	HUMAN PAPILLOMAVIRUS (HPV) AND CERVICAL INTRAEPITHELIAL NEOPLASIA IN WOMEN ATTENDING IN DIFERENTS PUBLIC HEALTH CENTERS FROM MARACAIBO, VENEZUELA	Carrero, Yenddy1, Callejas, Diana1, Alaña, Freddy 2, Silva, Chiquinquira3, Acuña, Elizabeth2, Roa, Daniela4, Duarte, Carla4, and Porto, Leticia1 1Laboratorio Regional de Referencia Virologica, Facultad de Medicina, 2Universidad del Zulia Servicio medico-
TM61	EVALUATION OF THE FLOCKED SWAB +UTM FOR COLLECTION OF CERVICAL SPECIMENS FOR MOLECULAR DETECTION OF HUMAN PAPILLOMA VIRUS	A.Verri.1, S. Castriciano2 and V.Grazioli1 1Molecular Department, Centro Diagnostico Italiano (Milano) and 2Copan Italia, Brescia, Italy